Sweet Financial Partners LLC Sells 5,196 Shares of CVS Health Co. (NYSE:CVS)

Sweet Financial Partners LLC lowered its position in CVS Health Co. (NYSE:CVS) by 19.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,209 shares of the pharmacy operator’s stock after selling 5,196 shares during the quarter. Sweet Financial Partners LLC’s holdings in CVS Health were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in CVS. Deerfield Management Company L.P. Series C bought a new position in shares of CVS Health during the second quarter valued at $57,584,000. CX Institutional raised its position in CVS Health by 698.0% during the 3rd quarter. CX Institutional now owns 74,609 shares of the pharmacy operator’s stock worth $4,691,000 after purchasing an additional 65,259 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its holdings in CVS Health by 27.9% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 665,451 shares of the pharmacy operator’s stock worth $39,302,000 after buying an additional 145,158 shares during the period. Steph & Co. grew its position in shares of CVS Health by 192.0% in the 1st quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock valued at $35,000 after buying an additional 288 shares during the last quarter. Finally, Douglas Lane & Associates LLC raised its position in shares of CVS Health by 1.6% during the first quarter. Douglas Lane & Associates LLC now owns 1,084,256 shares of the pharmacy operator’s stock worth $86,480,000 after acquiring an additional 16,840 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 2.1 %

CVS opened at $63.67 on Friday. The firm has a market capitalization of $79.93 billion, a PE ratio of 11.19, a P/E/G ratio of 0.93 and a beta of 0.54. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.86 and a quick ratio of 0.66. CVS Health Co. has a fifty-two week low of $52.77 and a fifty-two week high of $83.25. The company’s 50-day moving average is $59.73 and its 200 day moving average is $60.75.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.10. The company had revenue of $91.23 billion for the quarter, compared to analyst estimates of $91.41 billion. CVS Health had a return on equity of 12.72% and a net margin of 1.98%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.21 earnings per share. As a group, research analysts predict that CVS Health Co. will post 6.51 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Monday, October 21st will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date is Monday, October 21st. CVS Health’s payout ratio is currently 46.75%.

Wall Street Analyst Weigh In

CVS has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reduced their target price on CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Barclays upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $63.00 to $82.00 in a research report on Thursday, October 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $62.00 price target on shares of CVS Health in a report on Tuesday, October 1st. TD Cowen raised CVS Health from a “hold” rating to a “buy” rating and boosted their price objective for the company from $59.00 to $85.00 in a research note on Friday, October 4th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 target price on shares of CVS Health in a research note on Wednesday, September 4th. Nine investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $75.26.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.